Welcome to our dedicated page for Disc Medicine SEC filings (Ticker: IRON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Disc Medicine’s SEC documents are packed with clinical data, trial endpoints and cash-burn tables that easily stretch beyond 200 pages. Finding where a Phase 2 read-out moved the needle or which executive exercised stock options can feel like searching for a gene variant in a genome.
Stock Titan solves that problem. Our AI parses every new 10-Q quarterly earnings report, 10-K annual report and 8-K material event the moment IRON files with EDGAR. Plain-language summaries surface R&D spend, milestone payments and risk factors, while real-time alerts flag Disc Medicine insider trading Form 4 transactions so you never miss a director’s buy or sell. Need to answer “How do I read Disc Medicine’s proxy statement executive compensation section?”—we highlight the exact tables in seconds.
Use the platform to:
- Track pipeline progress through 8-K trial disclosures explained simply
- Compare quarter-over-quarter cash runway with AI-annotated 10-Q trends
- Monitor Disc Medicine Form 4 insider transactions real-time for confidence signals
- Dive into “Disc Medicine annual report 10-K simplified” to spot hepcidin-pathway strategy updates
Whether you type “understanding Disc Medicine SEC documents with AI” into ChatGPT or ask Google for “Disc Medicine earnings report filing analysis,” this page delivers. Every filing, every footnote—decoded, searchable and always current.
Atlas Venture and affiliated funds reported holdings in Disc Medicine, Inc. This Amendment No. 4 to a prior Schedule 13D discloses that multiple Atlas Venture funds collectively beneficially own 2,148,984 shares of Disc Medicine common stock, representing an estimated 6.2% of outstanding shares based on 34,765,581 shares outstanding as of July 31, 2025. Individual fund holdings are reported as Atlas Venture Fund X: 1,084,527 shares (3.1%), Atlas Venture Fund XII: 51,000 shares (0.1%), Atlas Venture Opportunity Fund I: 592,908 shares (1.7%), and Atlas Venture Opportunity Fund II: 420,549 shares (1.2%). The filing states these reporting persons have shared voting and dispositive power over their respective shares and notes they "may be deemed" a group but explicitly disclaim group membership. The amendment references recent transactions in Exhibit 99.1 and updates prior Schedule 13D disclosures.
Disc Medicine, Inc. (IRON) submitted a Form 144 proposing the sale of 7,212 shares of Common Stock through Merrill Lynch, with an aggregate market value of $440,653.20. The filing lists 34,765,581 shares outstanding and an approximate sale date of 08/14/2025 on Nasdaq. The shares were originally acquired in a private placement on 05/01/2020 from the issuer and paid in cash. The filer reports no securities sold in the past three months and includes the standard representation about no undisclosed material information and compliance with Rule 10b5-1 if applicable.
Disc Medicine, Inc. (IRON) filed a Form 144 reporting a proposed sale of 12,862 shares of common stock through Merrill Lynch One Bryant Park (New York) with an aggregate market value of $785,868.20. The filing states the company has 34,765,581 shares outstanding and lists the approximate sale date as 08/14/2025 on the Nasdaq.
The securities were originally acquired on 05/01/2020 in a private placement from the issuer, paid in cash. The filer reports no securities sold in the past three months and includes the standard representation that the seller does not possess undisclosed material adverse information. The notice includes the usual signature and legal attestation language.
Frazier-affiliated funds disclose their holdings in Disc Medicine (Common Stock, CUSIP 254604101). The largest single holding reported is 1,026,489 shares (3.0% of the class) held directly by Frazier Life Sciences Public Fund, L.P., with shared voting and dispositive power. Other direct holdings include 300,643 shares (0.9%) by Frazier Life Sciences Public Overage Fund, L.P., 264,484 shares (0.8%) by Frazier Life Sciences XI, L.P., and 63,218 shares (0.2%) by Frazier Life Sciences X, L.P.
The filing clarifies governance and attribution: several entities report shared voting and shared dispositive power over these positions and the Statement corrects any prior over-attribution of ownership to certain committee members. Percentages are calculated using 34,634,295 shares outstanding as stated in the filing.
Disc Medicine, Inc. (IRON) filed a Form 144 reporting a proposed sale of 24,962 shares of common stock, with an aggregate market value of $1,473,506.86, to be sold through Merrill Lynch One Bryant Park, New York on Nasdaq with an approximate sale date of 08/13/2025. The filing states the shares were acquired in a private placement from the issuer on 05/01/2020 and paid in cash on that date.
The form also lists multiple sale transactions by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. during July and August 2025, including a sale of 53,215 shares on 07/23/2025 for $3,244,656.91. The filing reports 34,765,581 shares outstanding for the issuer. No signature date or additional issuer relationship details are provided in the extract.
Disc Medicine (IRON) filed a Form 144 proposing the sale of 44,520 shares of common stock with an aggregate market value of $2,628,015.60, to be sold through Merrill Lynch on Nasdaq. The shares were acquired in a private placement on 05/01/2020 and the filing lists an approximate sale date of 08/13/2025. The filing also discloses multiple recent dispositions by Atlas Venture-related funds: a total of 145,916 shares sold in the past three months, generating approximately $8,905,720.24 in gross proceeds. The issuer has 34,765,581 shares outstanding per the form.
Wellington Management and affiliated entities report beneficial ownership of 1,432,090 shares of Disc Medicine, Inc. common stock, representing 4.13% of the class. The filing shows shared voting power over 1,074,282 shares and shared dispositive power over 1,432,090 shares; sole voting and dispositive powers are reported as 0. The securities are owned of record by clients of the listed Wellington investment advisers and are held in the ordinary course of business. The filing identifies Wellington Management Group LLP, Wellington Group Holdings LLP and Wellington Investment Advisors Holdings LLP as reporting entities and lists the relevant Wellington investment adviser subsidiaries that manage the client accounts holding these shares.
Disc Medicine (NASDAQ: IRON) filed its Q2-25 Form 10-Q. The clinical-stage biotech remains pre-revenue and focuses on hematologic programs bitopertin, DISC-0974 and DISC-3405.
- Cash, cash equivalents and marketable securities rose to $650.0 million (Dec-24: $489.9 m), driven by a January 2025 equity raise that netted $243 m.
- Q2 operating loss widened to $61.4 m (Q2-24: $30.9 m) as R&D expense nearly doubled to $46.3 m; SG&A increased to $15.1 m.
- Net loss was $55.3 m, or –$1.58/sh; 6-month loss was $89.3 m.
- Term-loan debt totals $30 m (net carrying value $28.7 m) under a Hercules facility maturing 2029; minimum-cash covenant waived while market cap ≥$1 bn.
- Milestone outflows: $10 m to Roche (Phase 3 start) and $3 m to AbbVie (Phase 2 start).
- Runway: management states funds are sufficient for at least 12 months and to support planned NDA submission (Oct-25) seeking accelerated approval of bitopertin for EPP/XLP.
Key pipeline events: APOLLO Phase 3 trial of bitopertin initiated May-25; Phase 2 readouts for DISC-0974 (MF & CKD anemia) expected 2H-25. The company also completed an asset acquisition (clinic-ready MDS program) with up to $50 m contingent payments.
FAQ
What is the current stock price of Disc Medicine (IRON)?
What is the market cap of Disc Medicine (IRON)?
